Vemurafenib combined with chidamide promotes senescence of secondary acute myeloid leukemia cells

Vemurafenib combined with chidamide promotes senescence of secondary acute myeloid leukemia cells

Objective To explore the effect of vemurafenib (VEM) combined with chidamide (CDM) on cellular senescence in secondary acute myeloid leukemia (sAML). Methods sAML cell lines SKM-1 and MOLM-13 were divided into control group (sAML cells), VEM group (sAML cells treated with VEM), CDM group (sAML cells...

Full description

Bibliographic Details
Main Authors:	ZHOU Qiao, LIANG Simin, CAI Duo, XIANG Wenqiong, WANG Li
Format:	Article
Language:	zho
Published:	Editorial Office of Journal of Army Medical University 2023-08-01
Series:	陆军军医大学学报
Subjects:	secondary acute myeloid leukemia vemurafenib chidamide cellular senescence
Online Access:	http://aammt.tmmu.edu.cn/html/202305030.htm

Similar Items

Vemurafenib induces senescence in acute myeloid leukemia and myelodysplastic syndrome by activating the HIPPO signaling pathway: implications for potential targeted therapy
by: Qiao Zhou, et al.
Published: (2024-01-01)

Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells
by: Haijun Zhao, et al.
Published: (2022-05-01)

Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance
by: Jianyu Peng, et al.
Published: (2023-07-01)

Efficacy and safety of an HDACi- and HMA-based protocol in adults with acute myeloid leukemia of intermediate- and adverse-risk categories: a retrospective study
by: Zhibo Guo, et al.
Published: (2023-12-01)

Acute and Persistent Remission of Aggressive Natural Killer Cell Leukemia in an Older Patient Induced by Chidamide Combined with Cyclophosphamide, Vindesine, Prednisone, and Etoposide Therapy
by: Qingqing Lin, et al.
Published: (2023-08-01)

Chidamide as maintenance after chemotherapy or hematopoietic stem cell transplantation in 27 children with T-cell lymphoblastic leukemia: A real-world prospective study
by: Xin-Yu Li, et al.
Published: (2023-02-01)

Case report: A case of classic hairy cell leukemia with CNS involvement treated with vemurafenib
by: Anna E. Johnson, et al.
Published: (2023-01-01)

Chidamide enhances cytotoxicity of doxorubicin by promoting autophagy and apoptosis in breast cancer
by: Jieqing Li
Published: (2023-04-01)

Optimal combination of immune checkpoint and senescence molecule predicts adverse outcomes in patients with acute myeloid leukemia
by: Peipei Wang, et al.
Published: (2023-12-01)

Clinical features of secondary acute myeloid leukemia in children
by: F. A. Makhacheva, et al.
Published: (2020-12-01)

Chidamide improves gefitinib treatment outcomes in NSCLC by attenuating recruitment and immunosuppressive function of myeloid-derived suppressor cells
by: Jinjin Shao, et al.
Published: (2024-04-01)

Synthesis and Crystal Structure Analysis of Histone Deacetylase Inhibitor Chidamide
by: Bo Han, et al.
Published: (2023-06-01)

Chidamide-based 3-drug combination regimen reverses molecular relapse post transplantation in AML1-ETO–positive acute myeloid leukemia
by: Yang Xi, et al.
Published: (2023-01-01)

Comparison of chemotherapy and chidamide combined with chemotherapy in patients with untreated angioimmunoblastic T-cell lymphoma
by: Simeng Gu, et al.
Published: (2024-04-01)

Identification of a venetoclax-resistance prognostic signature base on 6-senescence genes and its clinical significance for acute myeloid leukemia
by: Peng Ke, et al.
Published: (2023-11-01)

Chidamide and Oxaliplatin Synergistically Inhibit Colorectal Cancer Growth by Regulating the RPS27A-MDM2-P53 Axis
by: Li Z, et al.
Published: (2023-08-01)

Therapeutic Interaction of Apatinib and Chidamide in T-Cell Acute Lymphoblastic Leukemia through Interference with Mitochondria Associated Biogenesis and Intrinsic Apoptosis
by: Mengya Zhong, et al.
Published: (2021-09-01)

Identification of potential target genes of breast cancer in response to Chidamide treatment
by: Han Han, et al.
Published: (2022-11-01)

A Rare Cause of Uveitis: Vemurafenib
by: Selçuk Sızmaz, et al.
Published: (2018-12-01)

Acute myeloid leukemia secondary to acute B lymphoblastic leukemia treated with maintenance therapy in a child: A case report
by: Xiaoning Wang, et al.
Published: (2022-11-01)

SKIN TOXICITY OF TARGETED THERAPY: VEMURAFENIB, FIRST EXPERIENCES FROM MONTENEGRO
by: Todorović Vladimir, et al.
Published: (2015-07-01)

Loss of CD28 expression associates with severe T-cell exhaustion in acute myeloid leukemia
by: Yueting Huang, et al.
Published: (2023-03-01)

Sarcoid-like Granulomatous Intraocular Inflammation Caused by Vemurafenib Treatment for Metastatic Melanoma
by: Hilal Eser Öztürk, et al.
Published: (2020-01-01)

Successful Treatment of Pediatric Acute Myeloid Leukemia Presenting with Hyperbilirubinemia Secondary to Myeloid Sarcoma: A Case Report
by: Hwazen A. Shash, et al.
Published: (2022-11-01)

Selenylated Imidazo[1,2<i>-a</i>]pyridine Induces Cell Senescence and Oxidative Stress in Chronic Myeloid Leukemia Cells
by: Gabriella Teles Burkner, et al.
Published: (2023-01-01)

What’s New in the Classification, Diagnosis and Therapy of Myeloid Leukemias
by: Marco Pizzi, et al.
Published: (2023-03-01)

Long‐term observation of the frequency of secondary colorectal cancer and other malignancies in tyrosine kinase inhibitor treated chronic myeloid leukemia patients and controls
by: Nina Winkelmann, et al.
Published: (2022-08-01)

Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University
by: Kata Ferenczi, et al.
Published: (2023-11-01)

Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide
by: Jinghong Chen, et al.
Published: (2023-02-01)

In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors
by: Teresa Żołek, et al.
Published: (2023-07-01)

Chromosomal aberrations and prognostic analysis of secondary acute myeloid leukemia—a retrospective study
by: Mingzhu Song, et al.
Published: (2023-05-01)

Impact of Genetic Polymorphisms and Biomarkers on the Effectiveness and Toxicity of Treatment of Chronic Myeloid Leukemia and Acute Myeloid Leukemia
by: Carolina Alarcón-Payer, et al.
Published: (2022-09-01)

Vemurafenib and Dabrafenib Downregulates RIPK4 Level
by: Ewelina Madej, et al.
Published: (2023-02-01)

Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review
by: Qingqing Li
Published: (2023-12-01)

Myeloid Sarcoma as a Presentation of Acute Myeloid Leukemia and Blastic Phase in the Course of Chronic Myeloid Leukemia: A Case Report and Literature Review
by: Ugo Giordano, et al.
Published: (2023-07-01)

The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review
by: Hastono Ridwansyah, et al.
Published: (2023-09-01)

Pediatric chronic myeloid leukemia in myeloid blast crisis
by: Biswajit Dey, et al.
Published: (2023-04-01)

Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells
by: Carlotta Guzzetti, et al.
Published: (2023-09-01)

Phytochemicals and bioactive compounds effective against acute myeloid leukemia: A systematic review
by: Chukwuebuka Egbuna, et al.
Published: (2023-07-01)

Chronic myeloid leukemia : a handbook for oncologists and hematologists /
by: Mughal, Tariq I., author
Published: (2013)